Medtronic plc Reports Earnings Results for the Fourth Quarter and Full Year Ended April 26, 2024
May 23, 2024 at 06:45 am
Share
Medtronic plc reported earnings results for the fourth quarter and full year ended April 26, 2024. For the fourth quarter, the company reported sales was USD 8,589 million compared to USD 8,544 million a year ago. Net income was USD 654 million compared to USD 1,179 million a year ago. Basic earnings per share from continuing operations was USD 0.49 compared to USD 0.89 a year ago. Diluted earnings per share from continuing operations was USD 0.49 compared to USD 0.88 a year ago.
For the full year, sales was USD 32,364 million compared to USD 31,227 million a year ago. Net income was USD 3,676 million compared to USD 3,758 million a year ago. Basic earnings per share from continuing operations was USD 2.77 compared to USD 2.83 a year ago. Diluted earnings per share from continuing operations was USD 2.76 compared to USD 2.82 a year ago.
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows:
- general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.;
- cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.;
- vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.;
- spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity;
- neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%);
- diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps;
- neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc.
Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
MEDTRONIC PLC 
